Biogen Licenses Phase 2 Anti-Tau Antibody from Bristol-Myers Squibb

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/3/2026

1. SNOW
2. AVGO
3. RARE
4. HPE
5. FIVE
6. SPY
7. VRTS
8. NTAP
9. NTSK
10. OLLI

Go back to Biogen Licenses Phase 2 Anti-Tau Antibody from Bristol-Myers Squibb
BIOGEN IDEC Inc. (NASDAQ: BIIB) Delayed: 224.51 +1.84 (0.83%)
Previous Close $222.67    52 Week High $333.65 
Open $225.44    52 Week Low $223.02 
Day High $225.80    P/E 28.75 
Day Low $221.23    EPS $7.81 
Volume 550,726       

(NASDAQ: BIIBV) Delayed: 259.61 --0 (-0%)
Previous Close $259.61    52 Week High $ 
Open $0.00    52 Week Low $ 
Day High $259.61    P/E N/A 
Day Low $259.61    EPS $ 
Volume 19,000       

Bristol-Myers Squibb (NYSE: BMY) Delayed: 68.09 +0.43 (0.64%)
Previous Close $67.66    52 Week High $77.12 
Open $68.08    52 Week Low $49.03 
Day High $68.24    P/E 44.21 
Day Low $66.62    EPS $1.54 
Volume 6,224,153